GPC3 and hepatocellular carcinoma: Glypican-3 (GPC3) targeted CAR-T therapy, such as G3-28Z-41BBL CAR-T [77] and 32A9 CAR-T [78], displayed the cytolytic activities against GPC3+ HCC cells.